{
  "collectedOn": "2021-03-24T20:58:23.091Z",
  "fdaContentCurrentDate": "03/23/2021",
  "sourceUrl": "https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling",
  "tableHash": "4a3e348342f8dc75b03ff1cb6870b382",
  "table": [
    {
      "Drug": "Abacavir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Boxed Warning, Dosage and Administration, Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Abemaciclib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Abemaciclib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ado-Trastuzumab Emtansine",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Afatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Alectinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Alglucosidase Alfa",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "GAA",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Alpelisib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Alpelisib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Alpelisib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PIK3CA",
      "Labeling Sections": "Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Amifampridine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "NAT2",
      "Labeling Sections": "Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Amifampridine Phosphate",
      "Therapeutic Area": "Neurology",
      "Biomarker": "NAT2",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Amitriptyline",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Amoxapine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Amphetamine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Anakinra",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "NLRP3",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Anastrozole",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Drug Interactions, Clinical Studies"
    },
    {
      "Drug": "Arformoterol (1)",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Arformoterol (2)",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Aripiprazole",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Aripiprazole Lauroxil",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Arsenic Trioxide",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PML-RARA",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Articaine and Epinephrine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Articaine and Epinephrine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Atezolizumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Atezolizumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Gene Signature (T-effector)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Atezolizumab (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Atezolizumab (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Atezolizumab (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Atomoxetine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Ascorbic Acid, PEG-3350, Potassium Chloride, Sodium Ascorbate, Sodium Chloride, and Sodium Sulfate",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avapritinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PDGFRA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Avatrombopag (1)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "F2 (Prothrombin)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avatrombopag (2)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "F5 (Factor V Leiden)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avatrombopag (3)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROC",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avatrombopag (4)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROS1",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avatrombopag (5)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "SERPINC1 (Antithrombin III)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Avatrombopag (6)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Avelumab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Azathioprine (1)",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "TPMT",
      "Labeling Sections": "Dosage and Administration,  Warnings, Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology"
    },
    {
      "Drug": "Azathioprine (2)",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "NUDT15",
      "Labeling Sections": "Dosage and Administration, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology"
    },
    {
      "Drug": "Belinostat",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Dosage and Administration, Clinical Pharmacology"
    },
    {
      "Drug": "Binimetinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Binimetinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Blinatumomab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Boceprevir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Bosutinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Brentuximab Vedotin (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Brentuximab Vedotin (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "TNFRSF8 (CD30)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Brexpiprazole",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Brigatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Brivaracetam",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Bupivacaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Bupivacaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Bupropion",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Busulfan",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Cabozantinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RET",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Capmatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "MET",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Capecitabine",
      "Therapeutic Area": "Oncology",
      "Biomarker": "DPYD",
      "Labeling Sections": "Warnings and Precautions, Patient Counseling Information"
    },
    {
      "Drug": "Carbamazepine (1)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Boxed Warning, Warnings, Precautions"
    },
    {
      "Drug": "Carbamazepine (2)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "HLA-A",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Carglumic Acid",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "NAGS",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Cariprazine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Carisoprodol",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Carvedilol",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Ceftriaxone (1)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Ceftriaxone (2)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Celecoxib",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Ceritinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warning and Precautions, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Cerliponase Alfa",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "TPP1",
      "Labeling Sections": "Indications and Usage, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Cetuximab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Cetuximab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Cevimeline",
      "Therapeutic Area": "Dental",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Chloroprocaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Chloroprocaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Chloroquine",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions, Adverse Reactions"
    },
    {
      "Drug": "Chlorpropamide",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Cholic Acid",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "AMACR, AKR1D1, CYP7A1, CYP27A1, DHCR7, HSD3B2 (Bile Acid Synthesis Disorders)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Cisplatin",
      "Therapeutic Area": "Oncology",
      "Biomarker": "TPMT",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Citalopram (1)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Dosage and Administration, Warnings, Clinical Pharmacology"
    },
    {
      "Drug": "Citalopram (2)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Clobazam",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Clomipramine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Clopidogrel",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Boxed Warning, Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Clozapine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Cobimetinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Codeine",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information"
    },
    {
      "Drug": "Crizanlizumab-tmca",
      "Therapeutic Area": "Hematology",
      "Biomarker": "HBB",
      "Labeling Sections": "Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Crizotinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Crizotinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ROS1",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Dabrafenib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information"
    },
    {
      "Drug": "Dabrafenib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions, Adverse Reactions, Patient Counseling Information"
    },
    {
      "Drug": "Dabrafenib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions"
    },
    {
      "Drug": "Daclatasvir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Dacomitinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Dapsone (1)",
      "Therapeutic Area": "Dermatology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions, Use in Specific Populations, Patient Counseling Information"
    },
    {
      "Drug": "Dapsone (2)",
      "Therapeutic Area": "Dermatology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings and Precautions, Adverse Reactions, Patient Counseling Information"
    },
    {
      "Drug": "Dapsone (3)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions, Adverse Reactions, Overdosage"
    },
    {
      "Drug": "Darifenacin",
      "Therapeutic Area": "Urology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Dasabuvir, Ombitasvir, Paritaprevir, and Ritonavir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Dasatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Denileukin Diftitox",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IL2RA (CD25 antigen)",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Desipramine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Desflurane",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Genetic Susceptibility to Malignant Hyperthermia)",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Desvenlafaxine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Deutetrabenazine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Dexlansoprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Dextromethorphan and Quinidine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Diazepam",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Dinutuximab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "MYCN",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Docetaxel",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Dolutegravir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Donepezil",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Doxepin (1)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Doxepin (2)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Dronabinol",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Drospirenone and Ethinyl Estradiol",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Duloxetine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions"
    },
    {
      "Drug": "Durvalumab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Duvelisib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 17p",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Eculizumab (1)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "ACHR",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Eculizumab (2)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "AQP4",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Efavirenz",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "CYP2B6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Elagolix",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "SLCO1B1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Elbasvir and Grazoprevir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Elexacaftor, Ivacaftor, and Tezacaftor",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CFTR",
      "Labeling Sections": "Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Eliglustat",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Elosulfase",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "GALNS",
      "Labeling Sections": "Indications and Usage, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Eltrombopag (1)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "F5 (Factor V Leiden)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Eltrombopag (2)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "SERPINC1 (Antithrombin III)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Eltrombopag (3)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "Chromosome 7",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Eltrombopag (4)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "Chromosome 13",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Emapalumab-lzsg",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PRF1, RAB27A, SH2D1A, STXBP2, STX11, UNC13D, XIAP (Hemophagocytic Lymphohistiocytosis)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Enasidenib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IDH2",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Encorafenib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Encorafenib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Clinical Studies"
    },
    {
      "Drug": "Enfortumab Vedotin-ejfv",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NECTIN4",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Entrectinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ROS1",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Entrectinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NTRK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Erdafitinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies, Patient Counseling Information"
    },
    {
      "Drug": "Erdafitinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Eribulin (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Eribulin (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Erlotinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Erythromycin and Sulfisoxazole",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Escitalopram (1)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions"
    },
    {
      "Drug": "Escitalopram (2)",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Esomeprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Estradiol and Progesterone (1)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "PROC",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Estradiol and Progesterone (2)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "PROS1",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Estradiol and Progesterone (3)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "SERPINC1 (Antithrombin III)",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Eteplirsen",
      "Therapeutic Area": "Neurology",
      "Biomarker": "DMD",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Everolimus (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Everolimus (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Exemestane",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Fam-Trastuzumab Deruxtecan-nxki",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Fesoterodine",
      "Therapeutic Area": "Urology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Fosphenytoin",
      "Therapeutic Area": "Neurology",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Flibanserin (1)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Flibanserin (2)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Adverse Reactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Flibanserin (3)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Fluorouracil (1)",
      "Therapeutic Area": "Dermatology",
      "Biomarker": "DPYD",
      "Labeling Sections": "Contraindications, Warnings"
    },
    {
      "Drug": "Fluorouracil (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "DPYD",
      "Labeling Sections": "Warnings and Precautions, Patient Counseling Information"
    },
    {
      "Drug": "Fluoxetine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Flurbiprofen",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Flutamide",
      "Therapeutic Area": "Oncology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Fluvoxamine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions"
    },
    {
      "Drug": "Formoterol (1)",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Formoterol (2)",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Fulvestrant (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Fulvestrant (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Galantamine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Gefitinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Gefitinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Gemtuzumab Ozogamicin",
      "Therapeutic Area": "Onoclogy",
      "Biomarker": "CD33",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Gilteritinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FLT3",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Givosiran",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CPOX, HMBS, PPOX (Acute Hepatic Porphyria)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Glimepiride",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions, Adverse Reactions"
    },
    {
      "Drug": "Glipizide",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Glyburide",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Golodirsen",
      "Therapeutic Area": "Neurology",
      "Biomarker": "DMD",
      "Labeling Sections": "Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Goserelin",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Hydralazine",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "Nonspecific (NAT)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Hydroxychloroquine",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions, Adverse Reactions"
    },
    {
      "Drug": "Ibrutinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 17p",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Ibrutinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 11q",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ibrutinib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "MYD88",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Iloperidone",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Imatinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "KIT",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Imatinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Imatinib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PDGFRB",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Imatinib (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FIP1L1-PDGFRA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Imipramine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Indacaterol",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Inebilizumab-cdon",
      "Therapeutic Area": "Neurology",
      "Biomarker": "AQP4",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Inotersen",
      "Therapeutic Area": "Neurology",
      "Biomarker": "TTR",
      "Labeling Sections": "Adverse Reactions, Clinical Pharmacology"
    },
    {
      "Drug": "Inotuzumab Ozogamicin",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ipilimumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "HLA-A",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ipilimumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Microsatellite Instability, Mismatch Repair",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Ipilimumab (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Ipilimumab (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ipilimumab (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Irinotecan",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Isatuximab- irfc (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 17p",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Isatuximab- irfc (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 4p;14q",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Isatuximab- irfc (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 14q;16q",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Isoflurane",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Genetic Susceptibility to Malignant Hyperthermia)",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Isoniazid, Pyrazinamide, and Rifampin",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "Nonspecific (NAT)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Isosorbide Dinitrate",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYB5R",
      "Labeling Sections": "Overdosage"
    },
    {
      "Drug": "Isosorbide Mononitrate",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYB5R",
      "Labeling Sections": "Overdosage"
    },
    {
      "Drug": "Ivacaftor",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CFTR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Ivacaftor and Lumacaftor",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CFTR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Ivacaftor and Tezacaftor",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CFTR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Ivosidenib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IDH1",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Ixabepilone (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ixabepilone (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Lacosamide",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Lansoprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Lapatinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Lapatinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Lapatinib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "HLA-DQA1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Lapatinib (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "HLA-DRB1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Larotrectinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NTRK",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ledipasvir and Sofosbuvir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Lenalidomide",
      "Therapeutic Area": "Hematology",
      "Biomarker": "Chromosome 5q",
      "Labeling Sections": "Boxed Warning, Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Lenvatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Microsatellite Instability, Mismatch Repair",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Lesinurad",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Letrozole",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Lidocaine and Prilocaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lidocaine and Prilocaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Lidocaine and Tetracaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lidocaine and Tetracaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lofexidine",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Use in Specific Populations"
    },
    {
      "Drug": "Lonafarnib (1)",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "LMNA",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Lonafarnib (2)",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "ZMPSTE24",
      "Labeling Sections": "Indications and Usage, Use in Specific Populations"
    },
    {
      "Drug": "Lorlatinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Lorlatinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ROS1",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Lumasiran",
      "Therapeutic Area": "Urology",
      "Biomarker": "AGXT",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Luspatercept–aamt",
      "Therapeutic Area": "Hematology",
      "Biomarker": "HBB",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Lusutrombopag (1)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "F2 (Prothrombin)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lusutrombopag (2)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "F5 (Factor V Leiden)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lusutrombopag (3)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROC",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lusutrombopag (4)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROS1",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lusutrombopag (5)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "SERPINC1 (Antithrombin III)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Lutetium Dotatate Lu-177",
      "Therapeutic Area": "Oncology",
      "Biomarker": "SSTR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Mafenide",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings, Adverse Reactions"
    },
    {
      "Drug": "Margetuximab-cmkb (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Margetuximab-cmkb (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FCGR2A (CD32A)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Margetuximab-cmkb (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FCGR2B (CD32B)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Margetuximab-cmkb (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FCGR3A (CD16A)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Meclizine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Meloxicam",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Mepivacaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Mepivacaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Mercaptopurine (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "TPMT",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology"
    },
    {
      "Drug": "Mercaptopurine (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NUDT15",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Methylene Blue",
      "Therapeutic Area": "Hematology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Metoclopramide (1)",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYB5R",
      "Labeling Sections": "Use in Specific Populations"
    },
    {
      "Drug": "Metoclopramide (2)",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Use in Specific Populations, Overdosage"
    },
    {
      "Drug": "Metoclopramide (3)",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Metoprolol",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Metreleptin",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "LEP",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Midostaurin (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FLT3",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Midostaurin (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NPM1",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Midostaurin (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "KIT",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Migalastat",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "GLA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Mirabegron",
      "Therapeutic Area": "Urology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Mivacurium",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "BCHE",
      "Labeling Sections": "Warnings, Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Modafinil",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Mycophenolic Acid",
      "Therapeutic Area": "Transplantation",
      "Biomarker": "HPRT1",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Nalidixic Acid",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions, Adverse Reactions"
    },
    {
      "Drug": "Nebivolol",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Clinical Pharmacology"
    },
    {
      "Drug": "Nefazodone",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Neratinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Neratinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Nilotinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Nilotinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Niraparib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA, Genomic Instability (Homologous Recombination Deficiency)",
      "Labeling Sections": "Indication and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Nitrofurantoin",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings, Adverse Reactions"
    },
    {
      "Drug": "Nivolumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Nivolumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Nivolumab (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Microsatellite Instability, Mismatch Repair",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Nivolumab (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Nivolumab (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Nortriptyline",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Nusinersen",
      "Therapeutic Area": "Neurology",
      "Biomarker": "SMN2",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Obinutuzumab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "MS4A1 (CD20 antigen)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Olaparib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Olaparib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Olaparib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Olaparib (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA, Genomic Instability (Homologous Recombination Deficiency)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Olaparib (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Homologous Recombination Repair",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Olaparib (6)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PPP2R2A",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Olaratumab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PDGFRA",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Oliceridine",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Omacetaxine",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ombitasvir, Paritaprevir, and Ritonavir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Omeprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Oxymetazoline and Tetracaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Oxymetazoline and Tetracaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Ondansetron",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Osimertinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ospemifene (1)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Ospemifene (2)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "CYP2B6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Oxcarbazepine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Palbociclib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Palbociclib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Paliperidone",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Palonosetron",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Panitumumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Panitumumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Pantoprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Parathyroid Hormone",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "CASR",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Paroxetine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Patisiran",
      "Therapeutic Area": "Neurology",
      "Biomarker": "TTR",
      "Labeling Sections": "Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Pazopanib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Pazopanib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Peginterferon Alfa-2b",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Pegloticase",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Boxed Warning, Contraindications, Warnings and Precautions, Patient Counseling Information"
    },
    {
      "Drug": "Pembrolizumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Pembrolizumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CD274 (PD-L1)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Pembrolizumab (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Microsatellite Instability, Mismatch Repair",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Pembrolizumab (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Pembrolizumab (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ALK",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Pembrolizumab (6)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Tumor Mutational Burden",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Pemigatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FGFR2",
      "Labeling Sections": "Indication and Usage, Dosage and Administration, Clinical Studies"
    },
    {
      "Drug": "Perphenazine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Pertuzumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Pertuzumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Phenytoin (1)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Phenytoin (2)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Phenytoin (3)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "HLA-B",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Pimozide",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Precautions"
    },
    {
      "Drug": "Piroxicam",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Pitolisant",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Ponatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Pralsetinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CCDC6-RET, KIF5B-RET,  RET",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Prasugrel (1)",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Prasugrel (2)",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Prasugrel (3)",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP3A5",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Prasugrel (4)",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2B6",
      "Labeling Sections": "Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Primaquine (1)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Contraindications, Warnings, Precautions, Adverse Reactions, Overdosage"
    },
    {
      "Drug": "Primaquine (2)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "CYB5R",
      "Labeling Sections": "Precautions, Adverse Reactions"
    },
    {
      "Drug": "Probenecid",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Procainamide",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "Nonspecific (NAT)",
      "Labeling Sections": "Adverse Reactions, Clinical Pharmacology"
    },
    {
      "Drug": "Propafenone",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Propranolol",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Protriptyline",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Quinidine",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Quinine Sulfate (1)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Quinine Sulfate (2)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions"
    },
    {
      "Drug": "Rabeprazole",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Raloxifene",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Raltegravir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Ramucirumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "EGFR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ramucirumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Rasburicase (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Boxed Warning, Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Rasburicase (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYB5R",
      "Labeling Sections": "Boxed Warning, Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Regorafenib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Ribociclib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Ribociclib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Rimegepant",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Risdiplam",
      "Therapeutic Area": "Neurology",
      "Biomarker": "SMN1, SMN2",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Risperidone",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Rituximab",
      "Therapeutic Area": "Oncology",
      "Biomarker": "MS4A1 (CD20 antigen)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Rivaroxaban",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "F5 (Factor V Leiden)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Ropivacaine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Ropivacaine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Rosuvastatin",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "SLCO1B1",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Rucaparib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Rucaparib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Rucaparib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYP1A2",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Rucaparib (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA, Loss of Heterozygosity (Homologous Recombination Deficiency)",
      "Labeling Sections": "Warnings and Precautions, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Sacituzumab Govitecan-hziy",
      "Therapeutic Area": "Oncology",
      "Biomarker": "UGT1A1",
      "Labeling Sections": "Warnings and Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Satralizumab-mwge",
      "Therapeutic Area": "Neurology",
      "Biomarker": "AQP4",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Selpercatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RET",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies"
    },
    {
      "Drug": "Setmelanotide (1)",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "LEPR",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Setmelanotide (2)",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "PCSK1",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Setmelanotide (3)",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "POMC",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Sevoflurane",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "RYR1",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Simeprevir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Siponimod",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Dosage and Administration, Contraindications, Drug Interactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Sodium Nitrite (1)",
      "Therapeutic Area": "Toxicology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Sodium Nitrite (2)",
      "Therapeutic Area": "Toxicology",
      "Biomarker": "Nonspecific (Congenital Methemoglobinemia)",
      "Labeling Sections": "Boxed Warning, Warnings and Precautions"
    },
    {
      "Drug": "Sodium Oxybate",
      "Therapeutic Area": "Neurology",
      "Biomarker": "ALDH5A1 (Succinic Semialdehyde Dehydrogenase Deficiency)",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Sodium Phenylbutyrate",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "ASS1, CPS1, OTC (Urea Cycle Disorders)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration"
    },
    {
      "Drug": "Sofosbuvir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Sofosbuvir and Velpatasvir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Sofosbuvir, Velpatasvir, and Voxilaprevir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Succimer",
      "Therapeutic Area": "Hematology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Succinylcholine (1)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "BCHE",
      "Labeling Sections": "Warnings, Precautions"
    },
    {
      "Drug": "Succinylcholine (2)",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "Nonspecific (Genetic Susceptibility to Malignant Hyperthermia)",
      "Labeling Sections": "Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reactions"
    },
    {
      "Drug": "Sulfadiazine",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Warnings"
    },
    {
      "Drug": "Sulfamethoxazole and Trimethoprim (1)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Sulfamethoxazole and Trimethoprim (2)",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "Nonspecific (NAT)",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Sulfasalazine (1)",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Sulfasalazine (2)",
      "Therapeutic Area": "Gastroenterology",
      "Biomarker": "Nonspecific (NAT)",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Synthetic Conjugated Estrogens, A (1)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "PROC",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Synthetic Conjugated Estrogens, A (2)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "PROS1",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Synthetic Conjugated Estrogens, A (3)",
      "Therapeutic Area": "Gynecology",
      "Biomarker": "SERPINC1 (Antithrombin III)",
      "Labeling Sections": "Contraindications"
    },
    {
      "Drug": "Tafamidis",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "TTR",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Tafenoquine",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "G6PD",
      "Labeling Sections": "Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information"
    },
    {
      "Drug": "Talazoparib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRCA",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Talazoparib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Tamoxifen (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Tamoxifen (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "F5 (Factor V Leiden)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Tamoxifen (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "F2 (Prothrombin)",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Tamoxifen (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Tamsulosin",
      "Therapeutic Area": "Urology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Warnings and Precautions, Adverse Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Telaprevir",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "IFNL3 (IL28B)",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Tetrabenazine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Thioguanine (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "TPMT",
      "Labeling Sections": "Dosage and Administration, Warnings, Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Thioguanine (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NUDT15",
      "Labeling Sections": "Dosage and Administration, Warnings, Precautions, Clinical Pharmacology"
    },
    {
      "Drug": "Thioridazine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Contraindications, Warnings, Precautions"
    },
    {
      "Drug": "Ticagrelor",
      "Therapeutic Area": "Cardiology",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Tipiracil and Trifluridine (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Tipiracil and Trifluridine (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Tolazamide",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Tolbutamide",
      "Therapeutic Area": "Endocrinology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Tolterodine",
      "Therapeutic Area": "Urology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Warnings and Precautions, Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Toremifene",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR (Hormone Receptor)",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Tramadol",
      "Therapeutic Area": "Anesthesiology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Boxed Warning, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Patient Counseling Information"
    },
    {
      "Drug": "Trametinib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Trametinib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "G6PD",
      "Labeling Sections": "Adverse Reactions"
    },
    {
      "Drug": "Trametinib (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Trastuzumab (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Trastuzumab (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ESR, PGR (Hormone Receptor)",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Tretinoin",
      "Therapeutic Area": "Oncology",
      "Biomarker": "PML-RARA",
      "Labeling Sections": "Indications and Usage, Warnings, Clinical Pharmacology"
    },
    {
      "Drug": "Triheptanoin",
      "Therapeutic Area": "Inborn Errors of Metabolism",
      "Biomarker": "ACADVL, CPT2, HADHA, HADHB (Long-Chain Fatty Acid Oxidation Disorders)",
      "Labeling Sections": "Indications and Usage, Clinical Studies"
    },
    {
      "Drug": "Trimipramine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Precautions"
    },
    {
      "Drug": "Tucatinib",
      "Therapeutic Area": "Oncology",
      "Biomarker": "ERBB2 (HER2)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Umeclidinium",
      "Therapeutic Area": "Pulmonary",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Upadacitinib",
      "Therapeutic Area": "Rheumatology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Ustekinumab",
      "Therapeutic Area": "Dermatology and Gastroenterology",
      "Biomarker": "IL12A, IL12B, IL23A",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Valbenazine",
      "Therapeutic Area": "Neurology",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Valproic Acid (1)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "POLG",
      "Labeling Sections": "Boxed Warning, Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Valproic Acid (2)",
      "Therapeutic Area": "Neurology",
      "Biomarker": "Nonspecific (Urea Cycle Disorders)",
      "Labeling Sections": "Contraindications, Warnings and Precautions"
    },
    {
      "Drug": "Vemurafenib (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BRAF",
      "Labeling Sections": "Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information"
    },
    {
      "Drug": "Vemurafenib (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "RAS",
      "Labeling Sections": "Warnings and Precautions, Adverse Reactions"
    },
    {
      "Drug": "Venetoclax (1)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 17p",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (2)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "Chromosome 11q",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (3)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "TP53",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (4)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IDH1",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (5)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IDH2",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (6)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "IGH",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (7)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "NPM1",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venetoclax (8)",
      "Therapeutic Area": "Oncology",
      "Biomarker": "FLT3",
      "Labeling Sections": "Clinical Studies"
    },
    {
      "Drug": "Venlafaxine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Drug Interactions, Use in Specific Populations, Clinical Pharmacology"
    },
    {
      "Drug": "Viltolarsen",
      "Therapeutic Area": "Neurology",
      "Biomarker": "DMD",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Vincristine",
      "Therapeutic Area": "Oncology",
      "Biomarker": "BCR-ABL1 (Philadelphia chromosome)",
      "Labeling Sections": "Indications and Usage, Adverse Reactions, Clinical Studies"
    },
    {
      "Drug": "Voriconazole",
      "Therapeutic Area": "Infectious Diseases",
      "Biomarker": "CYP2C19",
      "Labeling Sections": "Clinical Pharmacology"
    },
    {
      "Drug": "Vortioxetine",
      "Therapeutic Area": "Psychiatry",
      "Biomarker": "CYP2D6",
      "Labeling Sections": "Dosage and Administration, Clinical Pharmacology"
    },
    {
      "Drug": "Voxelotor",
      "Therapeutic Area": "Hematology",
      "Biomarker": "HBB",
      "Labeling Sections": "Clinical Pharmacology, Clinical Studies"
    },
    {
      "Drug": "Warfarin (1)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "CYP2C9",
      "Labeling Sections": "Dosage and Administration, Drug Interactions, Clinical Pharmacology"
    },
    {
      "Drug": "Warfarin (2)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "VKORC1",
      "Labeling Sections": "Dosage and Administration, Clinical Pharmacology"
    },
    {
      "Drug": "Warfarin (3)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROS1",
      "Labeling Sections": "Warnings and Precautions"
    },
    {
      "Drug": "Warfarin (4)",
      "Therapeutic Area": "Hematology",
      "Biomarker": "PROC",
      "Labeling Sections": "Warnings and Precautions"
    }
  ]
}